Alexandra Aubry

New treatment options for resistent tuberculosis

Alexandra Aubry has been trained at the Medical school of Université Paris Diderot where she passed her MD Thesis (describing one of the largest cohort of M. marinum infections) in 1999. She started working on her PhD thesis on DNA gyrase in Mycobacterium tuberculosis in 2000 in the team of Vincent Jarlier, at the Université Pierre and Marie Curie (now Sorbonne-Université) in Paris and pursued this work during a postdoc in the group of Mark Fisher in London, an internationally well recognized expert in topoisomerases. In the meantime, she learned Medical Microbiology at the Bench in the Department of Bacteriology-Hygiene at Pitié-Salpêtrière hospital in Paris (head: Vincent Jarlier), where she became Assistant Professor (2000), Associated Professor (2006) and Professor (2016).
Alexandra Aubry works in the field of antibiotic resistance, especially focusing on mycobacteria and fluoroquinolones.
She is currently doing her research activity at the Cimi-Paris, Sorbonne-Université, in the team she leads “Emergence and Diffusion of Multiple Resistance against Antibiotics”. This team focuses on the mechanisms of emergence and diffusion of multiple drug resistance (MDR) in bacteria by using two models, (i) chromosome-born MDR in Mycobacterium tuberculosis (Mtb) and (ii) plasmid-born MDR in Enterobacteriaceae. Her group was pioneer in characterizing the enzymatic activities of mycobacterial DNA gyrases and determining the three-dimensional structure of M. tuberculosis DNA gyrase. She also recently filed a patent regarding new antituberculous drugs.

András Inotai

How to solve money gap to ensure patient access to pharmaceuticals in CEE counties

András Inotai PharmD, PhD, DrHabil is a graduate of Semmelweis Medical University in Budapest (PharmD, 2007), the Eötvös Loránd Science University in Budapest (Diploma in pharmaceutical policy and pharmacoeconomics, 2008), the Semmelweis University School of PhD Studies in Budapest (PhD in Pharmacoeconomics, 2011) and the Eötvös Loránd Science University in Budapest (Habilitation in Sociology, 2018). Dr. Inotai is a principal researcher of Syreon Research Institute and the Head of Pharmaceutical Policy Research. He has more than 12 years of research experience in pharmaceutical policy, pharmacoeconomics, health technology assessment and patient reported outcomes. He is also an assistant professor at Eötvös Loránd University (MSc in Health Policy, Finance and Analysis) leading the modules of Patient Reported Outcomes, Pharmaceutical policy and Pharmacoeconomics. Dr. Inotai was the president of ISPOR Hungary Chapter between 2014-15 and member of the ISPOR Central Eastern European Network Executive Committee (2013-2017). He was the co-editor of the ISPOR CEE Network Newsletter (2013-2017). He is author of 4 books, and more than 40 peer-reviewed scientific publications in health economics and pharmaceutical policy with a cumulative impact factor of 50.3.

Ann Langius-Eklöf

Smart phones provide smart patients

Ann Langius-Eklöf is a professor in nursing PhD, RN and leader of the research group I-CARE at the Division of Nursing. Head of Division of Nursing and responsible for the subject nursing and Deputy head of the Department of Neurobiology, Care Sciences and Society (NVS).
Her research focuses on the salutogenic perspective, which focuses on health, resources and subjective evaluations. Methodological and clinical studies on how patient reported outcomes such as quality of life, well-being, symptoms and satisfaction can be integrated in clinical care are performed. There are several individual factors influencing how a person perceives the situation in connection with a disease. One important factor is the person’s coping capacity defined by the concept Sense of Coherence (SOC). Sense of coherence reflects a person’s view of life on how comprehensible, manageable and meaningful life appears. The SOC scale is included as an important independent factor in the research studies. Ann Langius-Eklöf and her team have developed an interactive ICT-platform (an app-Interaktor) for symptom management and evaluate the effects concerning symptom burden, health-related quality of life, self-care, participation and recovery. The projects are based on their Participatory Care Model, which emphasizes on the integration of the person-centered perspective and the professional knowledge calling for a paradigm shift of how heath care is organized.

Ann Lykkegaard-Sorensen

Interprofessional approach for safer medication in psychiatry

Ann Lykkegaard Sørensen is a senior lecturer at the University College of Northern Denmark. She has carried out studies about errors in medication handling, inappropriate prescribing in psychiatry and most recently intercollaboration between physicians and nurses. Ann Lykkegaard Sørensen will present some perspectives on the importance of intercollaboration in medication safety.
Her background includes the following:
2010 – Master in Health Science from Aarhus University, Denmark
2010 – Lecturer at the Nursing Department at The University College of Northern Denmark
2016 – Senior lecturer
2017 – PhD

Anna-Karin Hamberg

Clinical use of pharmacokinetics

Anna-Karin Hamberg is a Pharmacist by training, and currently works as a clinical PK/PD-expert at the Department of Clinical Pharmacology, Uppsala University Hospital, Sweden. She received both her MSc in Pharmacy and PhD in Medical Sciences from Uppsala University. She has a long background as a regulatory expert in pharmacokinetics and pediatric clinical pharmacology, mainly from working as a pharmacokinetic assessor at the Swedish Medical Products Agency in Uppsala. But she has also served as a member of the Pediatric Committee (PDCO) at the European Medicines Agency (EMA), as a bioequivalence expert for WHO in Geneva and as a clinical pharmacologist at Roche in Basel. Her primary research interest is to develop and improve the hospitals therapeutic drug monitoring service through the integration of PK/PD-modeling and simulation into the clinic, sometimes referred to as model-informed precision dosing (MIPD).

Caridad Pontes García

Targeting small populations: barriers to market access

Caridad Pontes is a medical specialist in clinical pharmacology, she has been working mainly on drug development and regulation in different settings, from pharmaceutical industry to
academy and administration. Since 2016 she is in charge of drug appraisal and therapeutic
positioning at the Catalan Health System.
As associated professor at the Department of Pharmacology, Therapeutics and Toxicology at
Universitat Autònoma de Barcelona since 2011, she is teaching Pharmacology and Clinical
Pharmacology at the Medical School. Her recent research has been focused on improving
methods for drug development in small populations, pragmatic trials and
pharmacoepidemiology in mental health.

Dario Cattaneo

Antiinfectives in intensive care

Dr Cattaneo granted Pharmacy degree and post-degree specialization in Pharmacology (University of Milan) and PhD degree (Open University, UK). From 1997 to 2008 he was employed at the Mario Negri Institute for Pharmacological Research, Bergamo, as Head of the Unit of Pharmacology and Pharmacogenetics. Actually, Dr Cattaneo is employed at the Unit of Clinical Pharmacology, Luigi Sacco University Hospital (Milan). From 2012 he is also appointed as assistant professor of Pharmacology, Faculty of Medicine (University of Milan). Dr Cattaneo is Author of nearly 180 scientific articles published in peer-review journals (H-index 35, more than 4500 citations).

Denis O’Mahony

STOPP/START decision support for elderly prescribing

Prof. Denis O’Mahony, MD, FRCPI, FRCP (UK), has worked at senior faculty level in the Department of Medicine at the University College of Cork (Ireland) since 2005. He previously worked as Senior Lecturer in Geriatric Medicine at the University of Birmingham, UK, from 1995 to 1999. He worked as Consultant Physician in Geriatric Medicine to Cork University Hospital from 1999 to 2004. Since the mid-1990s, most of his research has focused on adverse pharmacotherapy in older people and its prevention. All of his research in recent years has focused on novel methods for optimizing pharmacotherapy in older people with multi-morbidity and its associated polypharmacy. He has collaborated closely with Prof. Stephen Byrne, Head of the UCC School of Pharmacy, in joint research work on pharmacotherapy optimization in older people since 2006.
Prof. O’Mahony is the original inventor and principal developer of STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria. STOPP was designed to detect potentially inappropriate medications (PIMs), START was designed to detect potential prescribing omissions (PPOs).
Prof. O’Mahony has over 170 peer-reviewed publications, details of most of which may be found at the following webpage: http://research.ucc.ie/profiles/C012/denisomahony

Harry Sokol

Gut microbiota - a new actor in pharmacology?

Harry Sokol is Professor in the Gastroenterology department of the Saint Antoine Hospital (APHP, Paris, France) and is the head of the Gut Microbiota and Immunity lab (INSERM CRSA UMRS 938, Sorbonne Université, Paris and INRA Micalis). Harry Sokol is an internationally recognized expert in Inflammatory Bowel Disease (IBD) and in gut microbiota fields. He has published over 170 papers on these topics in major journals (including Gut, Gastroenterology, Cell Metabolism, Cell Host & Microbe, Nature communication, Nature Medicine). His work on the role of the gut microbiota in IBD pathogenesis led to landmark papers describing the IBD-associated dysbiosis (imbalance in gut microbiota composition) and the role of the pivotal commensal bacteria Faecalibacterium prausnitzii in gut homeostasis and in IBD. Currently, his work focuses on deciphering the gut microbiota-host interactions in health and diseases (particularly IBD), in order to better understand their role in pathogenesis and develop innovative treatments. Harry Sokol is exploring particularly the role of the microbiota in tryptophan metabolism for which he is recipient of an ERC grant. Beside basic science, he is also involved in translational research. He is the current president of the French group of fecal microbiota transplantation, he coordinated a pilot randomized control trial evaluating fecal microbiota transplantation in Crohn’s disease and he is currently coordinating a phase III nationwide randomized control trial evaluating fecal microbiota transplantation in ulcerative colitis.

Henk Jan Guchelaar

Clinical implementation of pharmacogenetics

Prof. Dr. Henk Jan Guchelaar has completed his education Pharmacy (cum laude) and doctoral research at Groningen University, the Netherlands. The title of his doctoral thesis (1993) is ‘Modulation of cisplatin activity and toxicity; changing the drug or changing the target’. Guchelaar performed a clinical orientation at the New England Medical Centre Hospital in Boston, USA. After his graduation, Guchelaar further specialised in hospital pharmacy and clinical pharmacology at the University Medical Centre Groningen. In 2003, he was appointed professor Clinical Pharmacy at the LUMC, and in 2008 of the LACDR, University of Leiden. The title of his inaugural lecture was ‘(Bij)werking begrepen’.
Henk-Jan Guchelaar is professor Clinical Pharmacy at both the Leiden University Medical Center (LUMC) and the faculty of Math & Natural Sciences of the University of Leiden (LACDR). He is head of the department of Clinical Pharmacy & Toxicology of the LUMC and program leader of the research program ‘Personalised Therapeutics’. He is also director of the Leiden University research profile ‘Translational Drug Discovery and Development’ and founder of the Master Pharmacy. In addition, he coordinates a European Horizon 2020 project about implementation of pharmacogenetics in routine health care; Ubiquitous Pharmacogenomics (U-PGx). Guchelaar is chair of the board of division 4 of the LUMC. He is also clinical trainer Clinical Pharmacology and deputy clinical trainer Hospital Pharmacy.
Since more than 20 years, Henk-Jan Guchelaar performs research in the field of ‘Personalised Therapeutics’ with a strong focus on pharmacogenetics and oncology.
He has published over 300 scientific publications.

Jenny Kindblom

Pediatric clinical trials and their pitfalls

Jenny Kindblom is a specialist in clinical pharmacology with ten years’ experience from the Department of Clinical Pharmacology at Sahlgrenska University Hospital. Her main interest is pediatric clinical pharmacology. Since 2016 she is the medical director of the Pediatric Clinical Research Center, PCRC, at Queen Silvia Children´s Hospital at Sahlgrenska University Hospital. She is also an associate professor at the Institute of Medicine, the Sahlgrenska Academy.

Johan W. Mouton

Could PK/PD be the answer?

Johan W. Mouton, MD PhD FIDSA FAAM, is a consultant-microbiologist, Professor of PK/PD of antimicrobials and unit head R&D at the department of medical microbiology and infectious diseases at the Erasmus MC, Rotterdam. He was president of the International Society Anti-infective Pharmacology (ISAP, 2002-4) and one of the founding members of the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Pharmacology of Antimicrobials Study Group (EPASG 2010). He chaired the Dutch Working Party on Antibiotic Policy (SWAB) and editor of NethMap, is a member of the Dutch expert committee on the use of antimicrobials in animals (SDa) and a steering committee member of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). He was coordinator of several European projects. He has (co)-authored over 330 scientific publications (PubMed) and several books and book chapters. His H-index is 53 (web of science).

Markus Meyer

How to measure drug exposure

Markus Meyer holds a PhD in Metabolism of Methylenedioxy Designer Drugs from the Department of Experimental and Clinical Toxicology, Saarland University (Germany). He has previously worked as Associate Professor at Karolinska Institutet and at Heidelberg University.
Since 2016, he is working as Full Professor and Chair of the Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology, Center for Molecular Signaling (PZMS), at Saarland University.
He is also head of the 24/7 ClinTox laboratory of the Saarland University.
Markus Meyer has received several academic distinctions and awards, among others the “Young Scientists Award” (in 2008), Habilitation and Venia Legendi for Pharmacology and Toxicology (in 2014) and the “Victor Armstrong Award” (in 2017).

By attending Markus Meyer’s workshop on “How to measure drug exposure“, the learner will be able to describe strategies and workflows to analyze drugs and drugs of abuse for answering questions in the context of clinical toxicology.

Martina Schüssler-Lenz

10 years of Advanced Therapy Regulation in the European Union

Dr. Martina Schüssler-Lenz is the Chair of the Committee for Advanced Therapies (CAT) of the European Medicines Agency’s (EMA). The CAT is the committee responsible for evaluating the quality, safety and efficacy of marketing authorisations of cell and gene therapies (Advanced Therapy Medicinal Products, ATMPs).
Since 2005, she is working as M.D. at the Paul-Ehrlich Institute in the Section Advanced Therapies and Tissue Preparations. Martina is responsible for advising companies on drug development issues, reviewing clinical trials and marketing authorisations.
Overall, Martina has 30 years of professional experience. She received her medical degree in Germany at Mainz University. She completed an Internal Medicine residency, is board certified in internal medicine and worked many years in Hematology/Medical Oncology. Based on a grant from the German Research Council DFG she moved on to New York for a postdoctoral fellowship in tumor biology and immunology at the Memorial Sloan Kettering Cancer Center, followed by a fellowship at the Instituto Municipal de investigacion Medica in Barcelona, Spain.
She has been a member of the EMA Committee for Advanced Therapies for many years and was elected as its chairperson in February 2017.
Her scientific and regulatory work has resulted in several (co-)authorships in scientific journals, as for example recently the “Clinical development of CAR-T cells – challenges and opportunities in translating innovative treatment concepts” in EMBO Molecular Medicine.

Nicolas Picard

The use of social media in CPT teaching

Prof. Nicolas Picard leads a thematic group on digital pedagogy at the international francophone society of medical education (https://www.sifem.net/fr/numerique-pedagogie). He is a pharmacist, professor of pharmacology (head of the pedagogical department at the Faculty of Pharmacy) at Limoges University (France) and a hospital pharmacologist at Limoges University Hospital. Before joining the faculty of Pharmacy, he taught pharmacology at the faculty of Medicine, the institute of nursing and the school of midwifery between 2006 and 2012. In 2016, he joined a department on digital education in Health sciences (www.duenes.fr) at Limoges University with the objective of promoting the use of digital for pedagogy in pharmacy and its interface with the medical or paramedical sciences. He is particularly attached to the notion of “blended e-learning”, a hybrid principle combining face-to-face and digital activities. He is involved in different academic project related to (i) the development of interactive digital activities offered during lectures, (ii) student peer-evaluation, (iii) the use of in-situ and virtual simulation in pharmaceutical sciences, and (iv) the use of social networks to disseminate academic knowledge.

Ole Petter Ottersen

Global health research and education in Europe - how can clinical pharmacology contribute?

Ole Petter Ottersen has been President of Karolinska Institutet since August 2017, and previously served as President of the University of Oslo (2009-2017).
As a neuroscientist, physician and academic leader, Ottersen has held numerous positions of trust. Between 2013 and 2015, he was head of the Norwegian Association of Higher Education Institutions and of the Nordic University Association.

Ottersen served as chairman of the board for Norway’s National Program for Functional Genomics (2003-2007), as director of Norway’s Centre of Excellence in Molecular Biology and Neuroscience (2002-2009) and as coordinator of the Nordic Centre of Excellence in Molecular Medicine (2005-2009). He has also coordinated two projects under the EU Framework Program and was the panel leader for European Research Council Advanced Grants (2008-2012). He is currently the panel leader for ERC Synergy Grants.

In recent years, he has been engaged in global health – much inspired by his experiences as Chair of the Lancet-University of Oslo Commission on Global Governance for Health (2011-2014). The Commission examined the political determinants of health and produced the 2014 report, “The Political Origins of Health Inequity: Prospects for Change” that preceded the publication of UN’s Agenda 2030. He currently serves as a board member of the African Population and Health Research Center (APHRC) based in Nairobi.

Between 2006 and 2009, Ottersen was Chief Editor of Neuroscience, the official journal of the International Brain Research Organization, and has also served on numerous boards and prize committees, including the Kavli Prize Committee in Neuroscience and the Thon Foundation Advisory Board.

At the University of Oslo, Ottersen was Dean of Science within the medical faculty (2000-2002) and has taught medical students, physiotherapists and postgraduate students since 1976.

Stéphane Laurent

Update on treating hypertension

Stéphane Laurent is Emeritus Professor of Pharmacology in the Paris Descartes Medical School.
He was head of the Department of Clinical Pharmacology in the Hôpital Européen Georges Pompidou in Paris between 2008 and 2018, and head of INSERM U 970, team 7 in the Paris Cardiovascular Research Center (PARCC) between 2009 and 2018.
Professor Laurent has served as President of the European Society of Hypertension (ESH) (2007-2009), President of the ARTERY Society (2010-2012), and President of the French Society of Hypertension (2001-2002).
He is the co-author of the 2007, 2013 and 2018 ESH-ESC Guidelines for the management of Hypertension, and the 2009 ESH document on the reappraisal of hypertension guidelines. He is the author of over 400 referenced articles and 20 chapters in books.
His “h” index is 73 (Web of Science) with 15 “highly cited” papers, and the total number of citations of his articles is higher than 35,643 (Web of Science). Google Scholar’s H index is 84 with 66,659 citations.
Professor Laurent has delivered more than 350 invited lectures at international venues.

Sylvie Laporte

Meta-epidemiological studies to detect, quantify and adjust for bias in open-label trials

Sylvie Laporte is an assistant professor at the University Hospital of Saint-Etienne (France) since 2003, teaching physicians, pharmacists and statisticians. She is Head of Department of Clinical Pharmacology and a Member of the INSERM UNIT Sainbiose. Sylvie Laporte has a post-doctoral degree from Saint-Etienne University. Her field of research include clinical research on anticoagulants, meta-epidemiology and meta-analysis and meta-regression of pharmacological, clinical and epidemiological studies. She has experience of several multicenter trials (steering committee, data safety monitoring board, methodology, statistical analysis) and congress and meeting organization. She also has several national and European assignments, such as President of the French Society of Pharmacology and Therapeutics, Member of the National University Board on Pharmacology and Member of the Directorial Board of the University of Saint-Etienne.

Urs Meyer

2019 Lifetime Achievement Award

The EACPT is delighted to announce that the 2019 Lifetime Achievement Award of the European Association of Clinical Pharmacology and Therapeutics will go to Professor Urs Meyer from Switzerland.

The Award, which includes the EACPT silver medal, will be presented to Professor Meyer during the next EACPT congress in Stockholm, where he will also as an invited speaker present the lecture: “Therapeutic Lessons from Human Individuality”

Violeta Stoyanova-Beninska

Targeting small populations: drug designation and other regulatory challenges

Violeta Stoyanova-Beninska is currently working at the Medicines Evaluation Board, The Netherlands. In September 2018 Violeta has been elected as Chair of the Committee for Orphan Medicinal Products at the European Medicines Agency, of which she was a member from the Netherlands in the past 6 years. She was also Chair of the National Scientific and Regulatory Advice at MEB and member of the Scientific Advice Working party at EMA. Violeta Stoyanova is supervisor of PhD students, guest lecturer at Dutch universities, and she is involved in Regulatory Science research related to rare diseases, personalised medicine, psychiatry, neurology and human genetics.
Before moving to the regulatory area (2007), Violeta has been working in research and diagnostics in the field of clinical and molecular genetics (UHOG, ICGEB, Erasmus MC), and teaching and supervising medical students and PhDs, with main focus on monogenic disorders, cancer and epigenetics.

Wade Thompson

Prescribing vs deprescribing

Wade Thompson is a pharmacist and researcher. He has worked as a clinical pharmacist in primary care clinics and nursing homes. His research is focused on deprescribing and optimal medication use in older persons, and he was previously part of the Bruyère Research Institute Deprescribing Guidelines research team (deprescribing.org) in Ottawa, Canada. Wade Thompson is currently completing his PhD at the Research Unit of General Practice, University of Southern Denmark and is also affiliated with the hospital pharmacy research unit at Odense University Hospital.